[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First People's Hospital of Changzhou\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":254},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,74,104,128,150,174,193,213,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100582798","phase-3-safety-and-efficacy-of-combined-b-cell-depleting-therapy-and-daratumumab-in-autoimmune-encephalitis-100582798",false,"NCT06867991","Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis","RADIA","Inclusion Criteria:\n\n1. Aged 12 years and above\n2. Meet the diagnosis of autoimmune encephalitis and the target antigen is a neuronal surface antigen\n3. Have received at least 3 days of 500-1000mg high-dose methylprednisolone impulse treatment and IVIG (0.4g\u002Fkg\u002Fd for 5 consecutive days) or at least 5 plasma exchange\u002Fimmunoadsorption or at least 2 times of efgartigimod treatment\n4. mRS ≥ 3 points and neuropsychiatric manifestations inadequate to symptomatic treatment\n5. Informed consent or guardian signed informed consent\n\nExclusion Criteria:\n\n1. Severe active or chronic infection in the opinion of the investigator.\n2. Concurrently\u002Fpreviously participated in another clinical study involving investigational therapy within 4 weeks or 5 published half-lives of the investigational therapy (whichever is longer) before randomization.\n3. Women who are lactating or pregnant, or intend to become pregnant at any time within six months from study enrollment to the last dose of study drug.\n4. Known history of allergy or reaction to any component of the investigational drug formulation, or history of allergic reaction after any biological treatment.\n5. Any of the following at screening (one repeat test may be performed during the same screening period to confirm results prior to randomization):\n\n   Aspartate aminotransferase (AST) \\> 2.5 × upper limit of normal (ULN)\n\n   Alanine aminotransferase (ALT) \\> 2.5 × upper limit of normal (ULN)\n\n   Total bilirubin \\> 1.5 × ULN (unless due to Gilbert's syndrome)\n\n   Platelet count \\\u003C 75,000\u002FμL (or \\\u003C 75 × 109\u002FL)\n\n   Hemoglobin \\\u003C 8 g\u002FdL (or \\\u003C 80 g\u002FL)\n\n   Total white blood cell count \\\u003C 2,500 cells\u002Fmm3\n\n   Total immunoglobulins \\\u003C 600 mg\u002FdL\n\n   Absolute neutrophil count \\\u003C 1200 cells\u002FμL\n\n   CD4 T lymphocyte count \\\u003C 300 cells\u002FµL\n\n   Receipt of any experimental B cell depleting agent, unless CD19 B Cell levels have returned to above the lower limit of normal before randomization A history of severe drug allergies or anaphylaxis to two or more foods or drugs (including known sensitivity to acetaminophen\u002Fparacetamol, diphenhydramine or equivalent antihistamines, and methylprednisolone or equivalent glucocorticoids).\n\n   A known history of primary immunodeficiency (congenital or acquired) or underlying conditions, such as human immunodeficiency virus (HIV) infection or splenectomy, that predispose the participant to infection.\n\n   Any of the following received within 3 months before randomization Natalizumab (Tysabri®) Cyclosporin Methotrexate Mitoxantrone Cyclophosphamide Azathioprine\n6. Confirmed positive hepatitis B serology (hepatitis B surface antigen and core antigen) and\u002For positive hepatitis C PCR at screening.\n7. History of cancer, other than ovarian or extraovarian teratoma (also known as dermoid cyst) or germ cell tumor, or cutaneous squamous cell carcinoma or cutaneous basal cell carcinoma. Treatment of squamous cell carcinoma and basal cell carcinoma should have documented successful curative treatment more than 3 months before randomization.\n8. Received any live or attenuated vaccine (inactivated vaccine is acceptable) within 3 weeks before enrollment.\n9. Received BCG vaccine within 1 year before enrollment.","ALL","12 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Autoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR encephalitis can be severe and life-threatening. Anti-NMDAR autoantibodies against neurons are pathogenic and are mainly produced by autoreactive B cells and plasma cells. Therefore, early elimination of these abnormal immune cells is crucial for rapid improvement of the patient's condition. This study aims to explore the efficacy and safety of B cell depletion therapy (ofatumumab) followed by plasma cell depletion therapy (daratumumab) in the treatment of severe anti-NMDAR autoimmune encephalitis.",[26],"Anti-N-Methyl-D-Aspartate Receptor Encephalitis",[26,28,29,30],"Ofatumumab","Daratumumab","severe autoimmune encephalitis","RECRUITING","2026-06-05",{"date":34,"type":35},"2026-06-09","ACTUAL",{"date":37,"type":35},"2024-11-08",{"date":39,"type":20},"2027-11-08",{"name":41,"class":42},"The First People's Hospital of Changzhou","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100551163","regorafenib-and-sintilimab-in-combination-with-electroacupuncture-in-mss-crc-100551163","NCT06456515","Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC","A Single-Arm, Multicenter Phase II Clinical Study of Regorafenib and Sintilimab in Combination with Electroacupuncture in Patients with MSS Advanced Colorectal Cancer Who Have Failed More Than Second-Line Standard Chemotherapy","Inclusion Criteria:\n\n1. Fullly knowledge of the study and voluntarily sign the informed consent;\n2. Histologically and\u002For cytologically confirmed metastatic colorectal adenocarcinoma (Stage IV) with microsatellite stable (MSS)\\* confirmed by PCR or NGS;\n3. Receive at least two lines of standard chemotherapy in the past and have failed.\n4. No systemic chemotherapy or antitumor therapy such as radiotherapy, immunotherapy, biological or hormonal therapy in the past 4 weeks; and have never received VEGFR inhibitors\n5. Willing to receive electroacupuncture;\n6. Aged 18-75 years old (including 18 years old and 75 years old);\n7. Weighing more than 40 kg (including 40 kg);\n8. Able to take oral medication.\n9. Patients with adequate organ function at the time of enrollment are defined as follows: Neutrophil count ≥1500mm3 Platelet count ≥10.0 × 104\u002Fmm3 Hemoglobin (Hb) ≥ 9 g\u002FdL Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤100 U\u002FL (≤100 U\u002FL in patients with hepatocellular carcinoma, ≤250 U\u002FL in patients with liver metastasis) Total bilirubin ≤1.5 mg \u002FdL Creatinine ≤1.5 mg \u002FdL Lipase ≤ 80 IU\u002FL Urine Protein: one of the following (if any of the criteria are met, no other test may be performed) (i) Urine Protein (paper test) of 2+ or less (ii) UPC \\\u003C 3.5 (iii) Urine Protein ≦ 3500 mg for 24 hour urine protein measurements. mg Prothrombin time (PT)-International Normalized Ratio (INR): ≤ 1.5 (≤ 3.0 for anticoagulant administration)\n10. Eastern Cooperative Oncology Group Physical Performance Score (ECOG PS) ≤ 1 (0-1);\n11. Cardiac function evaluation: left ventricular ejection fraction ≥ 50% (echocardiography);\n12. Clearly meet the criteria for evaluating the efficacy of solid tumors (e.g., echocardiograms) Measurable lesions that meet the requirements of RECIST 1.1;\n13. Expected survival of more than 12 weeks.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if any of the following criteria are met.\n\n1. Patients who have received systemic chemotherapy, radiotherapy, surgery, hormonal therapy or immunotherapy \\\u003C2 weeks prior to enrolment. Immune checkpoint blockade pretreatment is permitted.\n2. Patients with a history of regorafenib administration.\n3. Patients with uncontrolled hypertension (systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥90 mmHg) despite multiple antihypertensive medications; and\n4. Patients with acute coronary syndromes (including myocardial infarction and unstable angina) and a history of coronary angioplasty or stenting within 6 months prior to enrolment;\n5. Patients with a large pleural effusion or ascites requiring drainage; and\n6. Patients with grade ≥ 3 active infection according to NCI CTC AE version 4.03; patients with symptomatic brain metastases; and patients with a history of coronary artery angioplasty or stenting within the previous 6 months.\n7. Patients with symptomatic brain metastases;\n8. Patients with partial or complete gastrointestinal obstruction;\n9. Patients with interstitial lung disease with active signs or symptoms;\n10. Patients who test positive for anti-HIV-1 antibody, anti-HIV-2 antibody, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV)\\* \\*Patients who test positive for anti-hepatitis B surface (HBs) or anti-hepatitis B core (HBc) antibodies and patients with hepatitis B virus (HBV)-DNA measurements that are greater than the sensitivity of the test will also be excluded. Patients with concurrent autoimmune disease\n11. Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease.\n12. Patients requiring systemic corticosteroids (excluding those given temporarily for testing, prophylactic administration for allergic reactions, or for the relief of swelling associated with radiotherapy) or immunosuppressive agents, or who have received such therapy \\\u003C14 days prior to study participation;\n13. Patients with a history or finding of class ≥III congestive heart failure according to the New York Heart Association functional class;\n14. Patients with epilepsy requiring pharmacological treatment;\n15. Patients with grade 3 or greater bleeding within 4 weeks prior to enrolment.\n16. Patients who have undergone major surgery (open heart or caesarean section, etc.), caesarean biopsy, or trauma within 28 days prior to enrolment. the same day of the week prior to the 4-week period may be enrolled (however, in the case of manual anastomosis without bowel resection, this should be within 14 days prior to enrolment);\n17. Patients with non-healing wounds, non-healing ulcers or non-healing fractures.\n18. Patients with a history of hypersensitivity reaction to any investigational drug, analogue or excipient.\n19. Women who are pregnant or breastfeeding or have the potential to become pregnant.\n20. Patients with contraindications to electroacupuncture therapy or patients for whom electroacupuncture is contraindicated in accordance with TCM syndromes.","18 Years","75 Years",{"count":54,"type":20},30,[56],"NA","The aim of this clinical trial is to find out whether Regorafenib and Sintilimab in combination with electroacupuncture works in treating participants with microsatellite stable (MSS) advanced colorectal cancer who have failed one or more second-line standard chemotherapy regimens. It will also learn about the efficacy and safety of the combination therapy. The main questions the trial aims to answer are:\n\nDoes combination therapy reduce the overall survival time ? What medical problems do people have when they take combination therapy?\n\nParticipants will\n\nRegorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing",[59],"Colorectal Cancer Metastatic",[61,62,63,64],"Regorafenib","Sintilimab","electroacupuncture","colorectal cancer","2025-02-13",{"date":67,"type":35},"2025-02-17",{"date":69,"type":35},"2024-05-01",{"date":71,"type":20},"2026-03",{"name":41,"class":42},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100532710","phase-4-efficacy-of-henagliflozin-for-weight-loss-in-obesity-without-diabetes-100532710","NCT06216340","Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes","Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n1. 18 years old≤age≤65 years old, regardless of gender and race\n2. Nondiabetic population: without hypoglycemic treatment, FPG\\\u003C7.0 mmol\u002Fl, PPG\\\u003C11.1 mmol\u002Fl, and HbA1c\\\u003C6.5%\n3. obesity: BMI≥28 kg\u002Fm2\n4. Stable weight: weight change less than 5kg in the past 3 months\n5. Ability to understand and sign the informed consent form\n\nExclusion Criteria:\n\n1. Allergies to Henagliflozin or its formulations;\n2. Participants have been definitely diagnosed with diabetes;\n3. HbA1c≥6.5 % or FPG≥7.0 mmol\u002Fl, or PPG≥11.1 mmol\u002Fl;\n4. Participants have used glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose linked transporter-2 (SGLT-2) inhibitors, or other weight loss related drugs within the past 3 months;\n5. History of bariatric surgery;\n6. Untreated or uncontrolled hypothyroidism\u002Fhyperthyroidism;\n7. High risk of urinary tract infection;\n8. Obesity induced by other endocrinologic disorders (e.g. Cushing's Syndrome);\n9. Diagnosis of congenital glucose-galactose malabsorption or familial renal glycosuria\n10. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 times the upper limit of the normal range (UNL); Total bilirubin (TBIL) ≥ 2.0 times the upper limit of the normal range;\n11. estimated glomerular filtration rate (eGFR)\\\u003C30 mL\u002Fmin\u002F1.73 m2 or end-stage kidney disease, or requiring dialysis;\n12. History of major depressive disorder or other severe psychiatric disorders, e.g. schizophrenia, bipolar disorder within the last 2 years;\n13. Uncontrolled treated\u002Funtreated hypertension (systolic blood pressure ≥160 mm Hg and\u002For diastolic blood pressure ≥100 mm Hg)\n14. myocardial infarction, unstable angina, revascularization surgery, or cerebrovascular diseases within the past 3 months;\n15. Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer) or other severe diseases, which in the investigator's opinion could interfere with the results of the trial;\n16. Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) within 24 months;\n17. Participation in a clinical trial within the last 3 months prior to screening;\n18. Previous history of gestational diabetes;\n19. Previous history of eating disorders;\n20. Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7-10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g. imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium);\n21. Diet attempts using herbal supplements or over-the-counter medications within 3 months before screening\n22. Any lifetime history of a suicidal attempt or a history of any suicidal behavior in the last month prior to randomization;\n23. Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the investigator\n24. Known or suspected abuse of alcohol or narcotics\n25. Subjects from the same house hold participating in the trial\n26. Other situations which were inappropriate to the trial, at the discretion of the investigator","65 Years",{"count":83,"type":20},300,[85],"PHASE4","This trial is conducted in China. The purpose of the 24-week trial is to investigate the efficacy of henagliflozin to induce body weight loss and the purpose of the extension is to evaluate the hypoglycemic effect of henagliflozin in obese subjects without diabetes.\n\nTrial has the following two periods: 1) A 12-week randomized, double-blind, placebo-controlled, multi-center trial for evaluating the efficacy of henagliflozin to induce body weight loss; 2) A 12-week multicenter randomized controlled open-label trial for evaluating the hypoglycemic effect of henagliflozin followed by a 24-week extension period.",[88,89,90],"Obese","Weight Loss","Pre-diabetes",[92,88,93,94],"Henagliflozin","Weight loss","Glucose","NOT_YET_RECRUITING","2024-01-11",{"date":98,"type":35},"2024-01-22",{"date":100,"type":20},"2024-02-15",{"date":102,"type":20},"2026-10-01",{"name":41,"class":42},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100495550","phase-2-sbrt-combined-with-ak104-to-treatment-relapsed-or-metastatic-escc-100495550","NCT05732662","SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC","SBRT Combined With PD-1\u002FCTLA-4 Dual Antibody to Overcome Anti-PD-1 Resistant in Relapsed or Metastatic Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* 1\\. age ≥ 18 years. 2. patients enrolled must be eligible for PD-1 treatment-naïve patients with recurrent or metastatic advanced esophageal squamous carcinoma with definite measurable recurrent or metastatic lesions.\n\n  3\\. have at least 2 or more clearly measurable lesions (maximum diameter of lesions≥1 cm and shortest diameter of ≥1.5 cm of lymph nodes according to RECIST v1.1), at least one of which is feasible for radiation therapy).\n\n  4\\. no congestive heart failure, unstable angina, or unstable arrhythmia within the last 6 months.\n\n  5\\. patient activity status score of 0-3 on the Eastern Cooperative Oncology Group (ECOG) scale with a life expectancy assessment of ≥ 3 months.\n\n  6\\. no previous serious abnormalities of hematopoietic, cardiac, pulmonary, hepatic, or renal function and immunodeficiency.\n\n  7\\. absolute T-lymphocyte values ≥ 0.5 times the lower limit of normal and neutrophils ≥ 2.0 × 109\u002FL; AST and ALT ≤ 3.0 times the upper limit of normal (≤ 5.0 times the upper limit of normal for hepatocellular carcinoma\u002Fmetastatic liver cancer); and creatinine ≤ 3.0 times the upper limit of normal, 1 week before enrollment.\n\n  8\\. patients must have the ability to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. pregnant gestational or lactating women. 2. those with a history of other malignant diseases in the last 5 years. 3. persons with a history of uncontrolled epilepsy, central nervous system disease, or psychiatric disorder whose clinical severity, as judged by the investigator, may prevent signing an informed consent form or affect patient compliance with medication.\n\n  4\\. clinically significant (i.e., active) heart disease such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmias requiring pharmacologic intervention, or a history of myocardial infarction within the last 12 months.\n\n  5\\. organ transplantation requiring immunosuppressive therapy. 6. Significant active infection or, in the judgment of the investigator, significant hematologic, renal, metabolic, gastrointestinal, endocrine dysfunction or metabolic disorder, or other serious uncontrolled concomitant disease.\n\n  7\\. hypersensitivity to any investigational drug component. 8. have a history of immunodeficiency, including testing positive for HIV or having other acquired or congenital immunodeficiency diseases, or a history of organ transplantation, or other immune-related diseases requiring long-term oral hormone therapy.\n\n  9\\. those who are undergoing acute or chronic TB infection (patients with positive T-spot test and suspicious TB foci on chest radiograph).\n\n  10\\. other conditions that the investigator considers unsuitable for enrollment.",{"count":112,"type":20},25,[114],"PHASE2","The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1\u002FCTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.",[117],"Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",[119],"SBRT, AK104","2023-02-08",{"date":122,"type":35},"2023-02-17",{"date":124,"type":20},"2023-04",{"date":126,"type":20},"2026-12",{"name":41,"class":42},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":16,"minAge":51,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100247376","phase-2-cytokine-induced-killer-study-for-patients-with-stage-ii-melanoma-100247376","NCT02498756","Cytokine-induced Killer Study for Patients With Stage II Melanoma","A Study of Ipilimumab Plus Cytokine-induced Killer Immunotherapy for Stage II Melanoma Patients","Inclusion Criteria:\n\n* Histological diagnosis of melanoma. AJCC Stage IV (any T, any N, M1), metastatic, progressive, refractory, melanoma.\n\nEastern Cooperative Oncology Group (ECOG) Performance Status ≤1. Serum albumin ≥3.0 gm\u002FdL.\n\nExclusion Criteria:\n\n* Age \\\u003C18-years-old. Active CNS metastases or carcinomatous meningitis. Patients with CNS lesions that have been treated and who have no evidence of progression in the brain on CT\u002FMRI for ≥1 month are eligible. Pregnant or nursing women due to the unknown effects of immunization on the developing fetus or newborn infant.",true,"80 Years",{"count":83,"type":20},[114],"For investigators' current experimental clinical trial, patients are given 4 injections of ipilimumab, given 3 weeks apart x 4 injections with or without cytokine-induced killer therapy. Investigators propose to test this dual therapy in patients with melanoma who have known stage I, metastatic melanoma. Investigators hypothesize that this form of combinatorial immunotherapy will result in tumor stabilization or shrinkage, significant prolongation of progression-free, disease-free or overall survival compared to the use of ipilimumab alone",[141],"Melanoma","2015-07-14",{"date":144,"type":20},"2015-07-15",{"date":146,"type":4},"2015-08",{"date":148,"type":20},"2040-08",{"name":41,"class":42},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":136,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100247241","phase-4-effect-of-cytokine-induced-killer-cells-for-advanced-malignant-gliomas-100247241","NCT02496988","Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas","A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas","Inclusion Criteria:\n\n* Subjects with documented histologically confirmed primary grade 4 advanced malignant glioma.\n* No more than 3 prior relapses or prior systemic treatments.\n* Recurrent disease documented by MRI after prior therapy.\n* Must have at least one site of bidimensionally measurable disease:\n\narchived tissue from the initial diagnosis of advanced malignant glioma or upon transformation to advanced malignant glioma are available for central review within approximately 4 weeks after enrollment.\n\n* Completed at least one full cycle of temozolomide of 200 mg\u002Fm2\u002Fday administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression.\n* Karnofsky performance status of 60 or more. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits.\n* At least 18 years old.\n* Both men and women must practice adequate contraception.\n* Informed consent.\n\nExclusion Criteria:\n\n* Progressed while on temozolomide.\n* Evidence of acute intracranial or intratumoral hemorrhage \\> Grade 1.\n* Not recovered from the toxic effects of prior therapy.\n* Pregnant or breast feeding.\n* History of diabetes mellitus.\n* Uncontrolled intercurrent illness.\n* Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.\n* HIV positive.\n* Diagnosis of another malignancy may exclude subject from study.",{"count":158,"type":20},120,[85],"The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.",[162,163],"Cytokine-Induced Killer Cells","Advanced Milignant Gliomas",[162,165,166],"Milignant Gliomas","Temozolomide","2015-07-13",{"date":142,"type":20},{"date":170,"type":4},"2015-07",{"date":172,"type":20},"2030-07",{"name":41,"class":42},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":136,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100247310","phase-2-treatment-of-cik-for-patients-with-refractory-non-hodgkin-lymphoma-100247310","NCT02497898","Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma","A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy\n\nExclusion Criteria:\n\n* patients refuse the therapy or have no tolerance for the therapy",{"count":182,"type":20},1000,[114],"The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and\u002For chemoresistant lymphomas.",[186],"Lymphoma, Non-Hodgkin","2015-07-12",{"date":144,"type":20},{"date":170,"type":4},{"date":191,"type":20},"2040-07",{"name":41,"class":42},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":136,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":212,"locationsCount":4},"100247074","phase-1-effect-of-cytokine-induced-killer-cells-for-stage-i-ii-malignant-gliomas-100247074","NCT02494804","Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas","A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Stage I-II Malignant Gliomas","Inclusion Criteria:\n\nHistologically confirmed intracranial Grade 1 or 2 anaplastic glioma or glioblastoma (astrocytic tumor, anaplastic oligodendroglioma, or oligoastrocytoma).\n\nReceived prior standard radiation for a Grade 3 or 4 astrocytic tumor with a minimum cumulative dose of 40 Gy administered.\n\nCompleted at least one full cycle of temozolomide of 200 mg\u002Fm2\u002Fday administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression.\n\nKarnofsky performance status of 60 or more. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits.\n\nAt least 18 years old. Both men and women must practice adequate contraception. Informed consent.\n\nExclusion Criteria:\n\nProgressed while on temozolomide. Evidence of acute intracranial or intratumoral hemorrhage \\> Grade 1. Not recovered from the toxic effects of prior therapy. Pregnant or breast feeding. History of diabetes mellitus. Uncontrolled intercurrent illness. Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.\n\nHIV positive. Diagnosis of another malignancy may exclude subject from study.",{"count":201,"type":20},80,[203,114],"PHASE1","The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.",[162,165],[162,165,166],"2015-07-08",{"date":209,"type":20},"2015-07-10",{"date":170,"type":4},{"date":172,"type":20},{"name":41,"class":42},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":136,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100246763","phase-2-cik-in-treating-patients-with-esophageal-cancer-100246763","NCT02490735","CIK in Treating Patients With Esophageal Cancer","A Randomized Controlled Study of Cytokine-induced Killer Cells (CIK) Treatment in Patients With Staging Ⅰ-Ⅲ of Esophageal Carcinoma","Inclusion Criteria:\n\n* Patients histologically confirmed esophageal carcinoma;\n* Patients with staging I-III of esophageal carcinoma;\n* Patients who had completed chemotherapy;\n* Patients who have a life expectancy of at least 12 weeks;\n* Eastern Cooperative Oncology Group (ECOG) performance status was 0-1;\n* The bone marrow functioned normally (WBC\\>4.0×10\\^9\u002FL, Hb\\>120 g\u002FL, Platelet(PLT)\\>100×10\\^9\u002FL);\n* The ECG results were normal, and the liver and kidney were functional.\n\nExclusion Criteria:\n\n* Patients who had distant metastases by imaging studies;\n* Patients with uncontrolled infection; underlying disease that was severe or life-threatening;\n* Patients who were lactating;\n* ECOG perform status ≥ 2;\n* Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment;\n* Patients who are pregnant or nursing;\n* Patients with active tuberculosis (highly positive skin tests allowed if no active disease);\n* Patients with disease that would preclude general anesthesia;\n* Patients with active intractable or uncontrollable infection.",{"count":221,"type":20},2000,[114],"Chemotherapy is the main treatment method for patients with Esophageal Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Esophageal Cancer.",[225],"Esophageal Squamous Cell Carcinoma","2015-07-02",{"date":228,"type":20},"2015-07-07",{"date":146,"type":4},{"date":231,"type":20},"2042-08",{"name":41,"class":42},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":4,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":136,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":253,"locationsCount":4},"100246520","phase-2-dc-vaccine-therapy-combined-with-cytokine-induced-killer-cell-in-treating-100246520","NCT02487550","DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating","Inclusion Criteria:\n\n* Histologically proven renal cell carcinoma\n* Age: \\> 18\n* WHO- ECOG Performance Status 0-1\n* At least one measurable tumor lesions according to the RECIST criteria.\n* Life expectancy more than 3 months\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal\u002Fsquamous cell carcinomas of the skin).\n* Patients with metastatic disease in the central nervous system (CNS).\n* Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.\n* Patients with acute or chronic infection including HIV.\n* Patients who are pregnant or nursing.\n* Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial.\n* Patients who receive corticosteroids or other immunosuppressive agents.\n* Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.",{"count":240,"type":20},1200,[114],"The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.",[244],"Renal Neoplasma",[246,247],"Renal neoplasma","CIK cells","2015-06-29",{"date":250,"type":20},"2015-07-01",{"date":146,"type":4},{"date":172,"type":20},{"name":41,"class":42},""]